Alkermes, Inc. (NASDAQ: ALKS) today announced topline results from a phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder. This randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 or placebo in 68 patients with binge eating disorder. While ALKS 33 demonstrated a significant reduction from baseline in the efficacy endpoint of self-reported weekly binge eating episodes, the reduction was not significantly different from that observed with placebo. Based on these results, the company has determined that future studies in the binge eating indication are less attractive than other potential alternatives and will not pursue further development of ALKS 33 in this area. ALKS 33 remains in development for other central nervous system indications based on the compound's favorable characteristics of once-daily dosing, limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors.
Despite improvements in the past decade, 22 per cent of all deaths among children under-five in the Kyrgyz Republic are still caused by undernutrition, according to a report launched today. Besides the loss of lives, the burden of undernutrition in the Kyrgyz Republic is also substantial in economic terms: estimated to be US$32 million annually. Scaling up nutrition interventions, therefore, is crucial to prevent loss of children s lives and is a strategic economic investment with high returns, according to the Situational Analysis - Improving Economic Outcomes by Expanding Nutrition Programming in the Kyrgyz Republic. The report was released at a meeting jointly organized by the Ministry of Health, UNICEF and the World Bank. "Undernutrition is a critical public health challenge, although it remains a hidden problem, " said Sabyrbek Djumabekov, Minister of Health of the Kyrgyz Republic.
Eating Disorder Hope Expands The Eating Disorder Specialist Library And Simplifies The Search For Eating Disorder Treatment
Eating Disorder Hope, a respected independent resource for individuals suffering from anorexia, bulimia, binge eating and other body image and eating disorders, has expanded its Eating Disorder Specialist Library to further help sufferers of anorexia, bulimia and binge eating disorder find treatment options. "The detailed outlines of treatment centers within the Eating Disorder Specialist Library will better serve eating disorder sufferers, their loved ones and treatment providers by simplifying their search for treatment, " said Jacquelyn Ekern, MS, LPC, founder of Eating Disorder Hope. The new Eating Disorder Specialist Library features detailed overviews and pictures of eating disorder treatment centers and providers. Many eating disorder sufferers and families find that reviewing the online "virtual brochures" offered in the Eating Disorder Specialist Library greatly simplifies their search for treatment.
A new study by University of North Carolina at Chapel Hill and Norwegian researchers has found that women with anorexia nervosa are much more likely to have both unplanned pregnancies and induced abortions than women who don't have the serious eating disorder. These results may be driven by a mistaken belief among women with anorexia that they can't get pregnant because they are either not having menstrual periods at all or are having irregular periods, said Cynthia M. Bulik, PhD, the study's lead author and director of the UNC Eating Disorders Program. "Anorexia is not a good contraceptive, " Bulik said. "Just because you're not menstruating, or because you're menstruating irregularly, doesn't mean you're not at risk for becoming pregnant." Physicians and other health care providers need to be aware of this as well, Bulik said.
Paul Kenny, an associate professor in the Department of Molecular Therapeutics on the Florida campus of The Scripps Research Institute, has been selected as the 2010 winner of the Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. The award, which includes an honorarium of $25, 000, was presented at Neuroscience 2010, the Society for Neuroscience's annual meeting held this year in San Diego, CA. The award is given each year to a scientist who has conducted research in the area of substance abuse and the brain and nervous system. The award is intended to encourage innovative research into the neurobiology of drug addiction. The Waletzky family established the award in 2003 in memory of Jacob P. Waletzky, who died at the age of 29 from cocaine-induced cardiac arrhythmia.